Test Price
800 AED✅ Home Collection Available
12S rRNA (MTRNR1) Gene Sequencing Test in Dubai, UAE | 800 AED
Executive Summary & Core Metrics
Test Name: 12S rRNA (MTRNR1) Gene Sequencing
Price: 800 AED
Turnaround Time: 14 Days (2 Weeks)
Sample Type: Whole Blood (EDTA) or Extracted DNA
Methodology: PCR + Bidirectional Sanger Sequencing
- Accuracy: 99.9% diagnostic sensitivity for targeted MTRNR1 variants (m.1555A>G, m.1494C>T).
- Home Service: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Support: Post-result physician-guided teleconsultation included.
- Insurance Verification: Direct real-time check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The 12S rRNA (MTRNR1) gene sequencing test is a targeted genetic analysis that detects pathogenic mitochondrial DNA variants strongly associated with aminoglycoside-induced ototoxicity and nonsyndromic hearing loss. This test is essential for personalized medication safety, particularly in the UAE's diverse population where specific mitochondrial haplogroups elevate the carrier frequency. By identifying high-risk variants before antibiotic administration, clinicians can prevent irreversible hearing loss.
| Feature | Our Test: 12S rRNA (MTRNR1) Sequencing | Closest Alternative: Full mtDNA Genome Sequencing |
|---|---|---|
| Precision | Targeted analysis of clinically actionable MTRNR1 variants (e.g., m.1555A>G, m.1494C>T) | Entire mitochondrial genome; may identify variants of uncertain significance requiring extensive interpretation |
| Methodology | PCR amplification with bidirectional Sanger sequencing (Gold Standard for single-gene interrogation) | Next-Generation Sequencing (NGS) with Sanger confirmation of relevant findings |
| Speed & Cost | 14-day TAT | 800 AED | 4–6 weeks | 2,000+ AED |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403 “Identifying mitochondrial 12S rRNA variants is a critical step in preventing iatrogenic hearing loss. In my practice, pre-therapeutic screening for these variants has guided safer antibiotic selection, particularly for patients with a family history of deafness or those requiring prolonged aminoglycoside therapy. A negative result reduces—but does not eliminate—the risk, and should be correlated with audiological assessment. Genetic counseling is integral to the testing process to ensure patients understand the implications for themselves and their families.”
🛑 Critical Medication Advisory
Do not alter or discontinue any prescribed medication regimen without direct consultation with your treating physician. A positive genetic finding indicates a heightened risk profile that should be documented in your medical records to guide future therapeutic decisions. This test result alone does not constitute a contraindication to all aminoglycosides if no suitable alternative exists, but it mandates enhanced monitoring and precautionary measures.
⚠️ Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not intended for standalone diagnosis of existing hearing loss. Clinical correlation with audiometry and ENT evaluation is mandatory. It is inconclusive for variants located outside the 12S rRNA gene. Parental or legal guardian consent is required for minors, in accordance with Federal Law No. 2 of 2019.
- Red Flags: Sudden sensorineural hearing loss, acute tinnitus, or vertigo occurring within days of aminoglycoside exposure constitutes a medical emergency. Immediate ENT assessment is required. This test is designed for pre-exposure risk stratification and is not suitable for acute diagnostic evaluation.
Patient FAQ & Clinical Guidance
1. What is the 12S rRNA test used for?
A: This is a targeted genetic test that identifies specific mitochondrial DNA variants (m.1555A>G and m.1494C>T) in the 12S rRNA gene. These variants dramatically increase the risk of permanent, irreversible hearing loss when aminoglycoside antibiotics are administered. The test is recommended for anyone with a family history of hearing loss, patients scheduled for prolonged antibiotic therapy (e.g., for tuberculosis, cystic fibrosis, or neonatal sepsis), and as part of pre-conception carrier screening in high-risk populations.
2. How is the sample collected and what is the turnaround time?
A: A standard peripheral blood draw (3 mL in an EDTA tube) is performed by our certified phlebotomists. We offer VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Alternatively, if a DNA sample has already been extracted, it can be submitted directly. The turnaround time from sample receipt at our Dubai Healthcare City laboratory is 14 business days.
3. Is pre-test counseling required and how are results interpreted?
A: Pre-test genetic counseling is highly recommended and is mandatory for minors under UAE Federal Law No. 2 of 2019. Our DHA-licensed genetic counselors conduct sessions in English or Arabic. A positive result indicates a high lifelong risk of aminoglycoside-induced ototoxicity and should be documented as a drug-allergy alert in your medical file. A negative result reduces the likelihood of these specific variants but does not eliminate the risk from other genetic or environmental causes. All reports include ICD-10-CM codes H90.3, Z14.8, and Z82.2 for insurance and medical record integration.
4. What is the cost of the test and do you accept insurance?
A: The total cost for the 12S rRNA (MTRNR1) Gene Sequencing test is 800 AED. We work with a wide range of UAE-based insurance providers. Our team can perform a direct real-time insurance verification via WhatsApp at +971 54 548 8731 to confirm your coverage and out-of-pocket costs before any sample collection.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
DNA Labs UAE operates under DHA Facility License Number 1143. Our laboratory information systems and data handling protocols fully comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
We maintain ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and ensure that all genetic data is stored with bank-level encryption, accessible only to authorized medical personnel with explicit patient consent. Our commitment to YMYL standards ensures that every test result is clinically validated and securely delivered.
Clinical & Logistical Metadata
| Test Name | 12S rRNA (MTRNR1) Gene Sequencing |
| Price (AED) | 800 AED |
| Turnaround Time | 14 Business Days |
| Sample Type / Matrix | Whole Blood (3 mL EDTA) or Extracted DNA (≥20 ng/μL) |
| Methodology Used | Targeted PCR Amplification + Bidirectional Sanger Sequencing |
| ICD-10-CM Code | H90.3, Z14.8, Z82.2 |
| LOINC Code | 53576-1 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians